Firms
Arkin Bio Capital
Arkin Bio Capital is the clinical-stage biotechnology investment fund within Arkin Capital’s Arkin Bio platform. Established in 2021, it finances clinical proof of concept and later-stage development, distinct from the group’s early-stage Arkin Bio Ventures funds. Pini Orbach is managing partner overseeing both sets of funds. Verified investments include Reunion Neuroscience’s Series A and HI-Bio’s January 2024 Series B. A 2026 SEC filing separately identifies Arkin Bio Capital L.P., its general partner and Arkin Bio Ventures II L.P., confirming that these are distinct vehicles. The reviewed primary manager pages do not disclose this fund’s closed capital; Arkin Capital’s aggregate AUM is not assigned as fund size.
- Founded
- —
- Type
- Venture capital
Funds0
No funds on record yet.
Team
Operations and support
 Pini OrbachManaging Partner |
Co-investing
HI-Bio$95M · 2024-01-04Human Immunology Biosciences (HI-Bio)$95M · 2024-01-04
ARCH Venture Partners- HI-Bio$95M · 2024-01-04
- HI-Bio$95M · 2024-01-04
Newleos Therapeutics$93M · 2025-02-13
Reunion Neuroscience$133M · 2024-05-02
- HI-Bio$95M · 2024-01-04
- Newleos Therapeutics$93M · 2025-02-13
FemHealth Ventures- Reunion Neuroscience$133M · 2024-05-02
Life Sciences at Goldman Sachs Alternatives- Newleos Therapeutics$93M · 2025-02-13
Longwood Fund- Newleos Therapeutics$93M · 2025-02-13
- Reunion Neuroscience$133M · 2024-05-02
MPM BioImpact- Reunion Neuroscience$133M · 2024-05-02
Palo Santo VC- Reunion Neuroscience$133M · 2024-05-02
Plaisance Capital Management- Reunion Neuroscience$133M · 2024-05-02